Innovative Respiratory Technology ALung Technologies specializes in advanced extracorporeal CO2 removal systems with the Hemolung RAS, positioning them as a key provider for hospitals and clinics seeking less invasive respiratory support solutions, especially in treating acute respiratory failure and COPD.

Recent Acquisition Opportunities Following its acquisition by LivaNova for $10 million in mid-2022, ALung shows potential for strategic growth and market expansion, making it attractive for partners interested in integrating cutting-edge respiratory devices into broader healthcare portfolios.

Growing Clinical Evidence With multiple clinical trials and milestones achieved in previous years, ALung demonstrates a strong foundation of clinical validation, increasing credibility and appeal to healthcare providers seeking proven respiratory support technologies.

Funding and Development Focus Having secured significant funding in recent years, including $36 million in Series C financing, ALung is positioned to invest in product development and expand its market reach, presenting opportunities for partners involved in medical device distribution.

Targeted Market Segment ALung's focus on treating acute respiratory failure and COPD with innovative devices creates opportunities for partnerships with hospitals, health systems, and respiratory care providers aiming to adopt next-generation, minimally invasive treatment options.